CTOs on the Move

Nature`s Fynd

www.naturesfynd.com

 
Nature`s Fynd is a Chicago-based food com­pa­ny creating versatile alternative proteins to nourish the world`s grow­ing population while nurturing the planet. Born out of research conducted for NASA on microbes in Yellowstone National Park, the company`s break­through technology produces Fy™. Fy is a new-to-the-world, nutritional fungi protein that only uses a frac­tion of the resources required by traditional agriculture. We use Fy to make delicious, nutritious, and sustainable meat and dairy alternatives.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Mikael Bundgaard-Nielsen
Chief Technology Officer Profile

Funding

Nature`s Fynd raised $80M on 03/24/2020
Nature`s Fynd raised $45M on 12/08/2020

Similar Companies

The LIVEKINDLY Co

The LIVEKINDLY co. is a collective of plant-based heritage and start-up brands including The Fry Family Food Co., LikeMeat, and LIVEKINDLY.

Arizona Farm Bureau

We tweet about Arizona grown food, recipes, farms, and more. We are the voice of Arizona Agriculture. #thankafarmer

DandW Fine Pack

D&W Fine Pack, a customer-focused leader in the foodservice packaging industry

Justin's

Justins is an American brand of natural and organic nut butters and peanut butter cups.

Neptune Technologies and Bioressources

Neptune is a biotechnology company engaged primarily in the development and commercialization of marine-derived omega-3 polyunsaturated fatty acids ("PUFAs"). Neptune has a patented process of extracting oils from Antarctic krill, and principally sells omega-3 PUFAs as bulk oil to Neptune`s distributors who commercialize them under their private label primarily in the U.S., European and Australian nutraceutical markets. Neptune`s products generally come in bulk oil or capsule form and serve as a dietary supplement to consumers. Neptune`s head office is located at 545 Promenade du Centropolis, Suite 100, Laval, Quebec. Neptune respectively holds approximately 49% of the participating and voting rights of Acasti and 96% of the voting rights of NeuroBio. Through these subsidiaries, Neptune is also pursuing opportunities in the medical food and prescription drug markets. Acasti and NeuroBio respectively focus on the research and development of safe and therapeutically effective compounds for highly prevalent atherosclerotic conditions, such as cardiometabolic disorders and cardiovascular diseases, and for neurodegenerative and inflammation related conditions. Acasti`s lead prescription drug candidate is CaPre(R), a purified high omega-3 phospholipid concentrate derived from Neptune krill oil being developed to address the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia, which is characterized by abnormally high levels of triglycerides.